The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Subscribe To Our Newsletter & Stay Updated